A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Recruiting now Phase 1/2 NCT06618287

Run by Bristol-Myers Squibb · for 18 and older · All sexes

What this study is about

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Who can join (things the study team will check)

✅ You may be able to join if…

Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Participants must have a life expectancy of at least 3 months at the time of the first dose.
Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed
Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC.
Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC.
Group D: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC per ASCO/CAP criteria, based on the most recently analyzed biopsy or another pathology specimen.
Group E: Participants must have pathologically confirmed locally advanced or metastatic NSCLC, not amenable to treatment in curative intent.

🚫 You may not be able to join if…

Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
Participants with known mutations in EGFR will be excluded (Group A,B and E).
Participants must not have a history of serious recurrent infections.
Participants must not have a history of severe heart disease.
Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

University of Alabama at Birmingham, Birmingham, Alabama, United States
University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida, United States
Local Institution - 0125, Maywood, Illinois, United States
Local Institution - 0065, Iowa City, Iowa, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Cleveland Clinic, Cleveland, Ohio, United States
Local Institution - 0102, Columbus, Ohio, United States
Local Institution - 0134, Portland, Oregon, United States
Local Institution - 0052, Portland, Oregon, United States
Local Institution - 0090, Portland, Oregon, United States
Local Institution - 0014, Pittsburgh, Pennsylvania, United States
University of Tennessee Medical Center, Knoxville, Tennessee, United States

+ 52 more sites.

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06618287.

Open the interactive checklist for this trial →

Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.

Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.